Theravance Biopharma Inc

Total Valuation

Theravance Biopharma Inc carries a market capitalization of 884.18M, placing it among publicly traded companies globally. Its enterprise value stands at 533.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Theravance Biopharma Inc currently has 51.89M shares outstanding.

Valuation Ratios

Theravance Biopharma Inc trades at a trailing price-to-earnings ratio of 16.14. The price-to-sales ratio is 8.33, and the price-to-book ratio stands at 3.04.

Enterprise Valuation

On an enterprise value basis, Theravance Biopharma Inc trades at an EV/EBITDA multiple of 45.47 and an EV/FCF ratio of 9.73. The EV/Sales ratio of 5.11 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 55.82 provides insight into valuation relative to core operating earnings.

Financial Position

Theravance Biopharma Inc maintains a current ratio of 13.54, meaning it holds 13.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.31, indicating elevated leverage, while an interest coverage ratio of 10.15 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Theravance Biopharma Inc posts a return on equity of 20.91 and a return on invested capital of 2.78.

Taxes

Over the trailing twelve months, Theravance Biopharma Inc has paid 5.11M in income taxes, reflecting an effective tax rate of 8.67.

Stock Price Statistics

Theravance Biopharma Inc's stock has gained approximately 19.00769% over the past 52 weeks. The 50-day moving average sits at 16.97, while the 200-day moving average is 17.16.

Income Statement

Over the trailing twelve months, Theravance Biopharma Inc generated 104.31M in revenue and converted that into 53.81M in net income, yielding earnings per share of 1.04. EBITDA reached 11.72M, while operating income came in at 9.55M.

Balance Sheet

Theravance Biopharma Inc holds 387.66M in cash and equivalents against 38.57M in total debt, resulting in a net debt position of -219.77M. Total book value stands at 289.71M, with working capital of 385.90M providing operational flexibility.

Cash Flow

Theravance Biopharma Inc produced 53.74M in operating cash flow over the past twelve months. After subtracting -8,000.00 in capital expenditures, free cash flow totaled 53.73M - equivalent to 1.05 per share.

Margins

Theravance Biopharma Inc operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 9.15 and net profit margin of 51.58 provide insight into operational efficiency.

Dividends & Yields

Scores

Theravance Biopharma Inc posts an Altman Z-Score of 1.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.